MiNK Therapeutics, Inc. (INKT) Stock Forecast
INKT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $39.00 average of analyst targets
- Upside to target
- +314.5% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.35
- 52-week range
- $8.56 – $14.97
INKT analyst ratings
2 analystsNumber of analysts at each rating.
INKT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
INKT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.35 | −$0.35 | −$0.65 | +46.2% | 1 |
| Current fiscal year (2026) | −$1.93 | −$1.93 | −$1.93 | −$2.93 | +34.1% | 1 |
| Next fiscal year (2027) | −$1.97 | −$1.97 | −$1.97 | −$1.93 | −2.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
INKT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.6M | $1.6M | $1.6M | 0.0% | 1 |
| Current fiscal year (2026) | $3.4M | $3.4M | $3.4M | 0.0% | 1 |
| Next fiscal year (2027) | $4.0M | $4.0M | $4.0M | +17.6% | 1 |
INKT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
INKT revenue: reported and forecast
INKT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.91 | −$0.63 | −$0.63 | −$0.63 | −$0.35 | −61.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.46 | −$2.46 | −$1.93 | −$1.93 | −$1.93 | −21.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.85 | −$2.85 | −$2.65 | −$2.65 | −$1.97 | −31.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
INKT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; INKT beat in 7 of 12.
What analysts expect from INKT
2 analysts cover MiNK Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $39.00, 314.5% above the latest close of $9.41. Analysts expect earnings of −$1.93 per share for 2026, +34.1% from a year earlier. For 2027 the average estimate is −$1.97 per share on revenue of $4.0 million. MiNK Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: INKT income statement, INKT key metrics, INKT chart. See the INKT stock overview for the latest quote and news.
INKT forecast FAQ
What is MiNK Therapeutics's price target?
The average analyst price target for MiNK Therapeutics is $39.00, 314.5% above the latest close of $9.41.
Is MiNK Therapeutics a buy, hold or sell?
Of 2 analysts covering MiNK Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MiNK Therapeutics's EPS forecast?
Analysts forecast −$1.93 per share for 2026 (range −$1.93 to −$1.93); for 2027 the estimate is −$1.97.
What is MiNK Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $3.4 million, growth of 0.0%; for 2027 it is $4.0 million.
When does MiNK Therapeutics report earnings?
MiNK Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.35.
Does MiNK Therapeutics usually beat earnings estimates?
MiNK Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.